LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Elenco Azioni・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

212.06 -2.55

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

212.06

Massimo

218.93

Metriche Chiave
By Trading Economics
Entrata	-58M -13M
Vendite	-7.9M 52M
P/E Media del settore	28.708 51.415
EPS	1.63
Margine di Profitto	-25.801
Dipendenti	47
EBITDA	-49M 17M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+26.45% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.6B 4.4B
Apertura precedente	214.61
Chiusura precedente	212.06

Notizie sul Sentiment di mercato

By Acuity

67%

33%

305 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

102.5 / 109.24 Supporto e resistenza

Ligand Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 mag 2026, 22:47 UTC

Azioni calde

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mag 2026, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mag 2026, 22:00 UTC

I principali Market Mover

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mag 2026, 18:09 UTC

I principali Market Mover

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mag 2026, 16:02 UTC

Utili

I principali Market Mover

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mag 2026, 14:55 UTC

I principali Market Mover

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 mag 2026, 14:43 UTC

I principali Market Mover

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 mag 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mag 2026, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mag 2026, 21:16 UTC

Discorsi di Mercato

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 mag 2026, 20:19 UTC

Azioni calde

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mag 2026, 19:41 UTC

Acquisizioni, Fusioni, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mag 2026, 19:35 UTC

Discorsi di Mercato

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mag 2026, 18:35 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mag 2026, 17:28 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mag 2026, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mag 2026, 16:24 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

15 mag 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 mag 2026, 15:55 UTC

Discorsi di Mercato

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mag 2026, 15:20 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 mag 2026, 15:20 UTC

Discorsi di Mercato

Silver Plunges on Inflation Worries -- Market Talk

15 mag 2026, 15:20 UTC

Utili

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 mag 2026, 14:33 UTC

Discorsi di Mercato

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Confronto tra pari

Modifica del prezzo

Ligand Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

26.45% in crescita

Previsioni per 12 mesi

Media 279.71 USD 26.45%

Alto 330 USD

Basso 255 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ligand Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Ligand Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

102.5 / 109.24Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

305 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.